Nature Communications · 2019 · 189 citations · 40 references
Life SciencesNeuroscienceToxicologyMolecular NeuroscienceNeurochemistryNeurodegenerationAlzheimer DiseaseBlood-brain Barrier DeliveryBlood-brain Barrier ToxicityNanomedicineNeurodegenerative DiseasesNeurodegenerative DisordersAmyloid Beta AggregationAmyloid Beta PeptidesAmyloid InhibitionAmyloid ToxicityAmyloid-beta-induced NeurotoxicityCasein NanoparticlesNanoparticle NeurotoxicityNeuronal Dysfunction
Abstract Alzheimer’s disease (AD) is the most prevalent form of neurodegenerative disorders, yet no major breakthroughs have been made in AD human trials and the disease remains a paramount challenge and a stigma in medicine. Here we eliminate the toxicity of amyloid beta (Aβ) in a facile, high-throughput zebrafish ( Danio rerio ) model using casein coated-gold nanoparticles (βCas AuNPs). βCas AuNPs in systemic circulation translocate across the blood brain barrier of zebrafish larvae and sequester intracerebral Aβ 42 and its elicited toxicity in a nonspecific, chaperone-like manner. This is evidenced by behavioral pathology, reactive oxygen species and neuronal dysfunction biomarkers assays, complemented by brain histology and inductively coupled plasma-mass spectroscopy. We further demonstrate the capacity of βCas AuNPs in recovering the mobility and cognitive function of adult zebrafish exposed to Aβ. This potent, safe-to-use, and easy-to-apply nanomedicine may find broad use for eradicating toxic amyloid proteins implicated in a range of human diseases.
40
Measurement of protein using bicinchoninic acid
Pam Smith, Randall I. Krohn, Greg T. Hermanson et al. · Analytical Biochemistry · 1985 · 18.4K citations
The zebrafish reference genome sequence and its relationship to the human genome
Kerstin Howe, Matthew D. Clark, Carlos Torroja et al. · Nature · 2013 · 5.1K citations · Full text
Life Sciences, Biology, Genetics +17
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Neurology, Pharmacology +17
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text
Medicine, Neurology, Neuroscience +14